|
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). |
|
|
Consulting or Advisory Role - Genentech/Roche |
|
|
Stock and Other Ownership Interests - Perthera |
Honoraria - Caris Life Sciences; Celgene; Merrimack; Sirtex Medical |
Consulting or Advisory Role - AstraZeneca/MedImmune; Caris Life Sciences; Celgene; Perthera; RenovoRx; Sirtex Medical |
Research Funding - ARMO BioSciences (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Curegenix (Inst); FibroGen (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Caris Life Sciences; Perthera; Sirtex Medical |
|
|
Consulting or Advisory Role - Bayer |
Research Funding - EMD Serono; Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genentech/Roche |
Research Funding - Genentech/Roche |
Patents, Royalties, Other Intellectual Property - Genentech/Roche |
Travel, Accommodations, Expenses - Genentech/Roche |
Other Relationship - Genentech/Roche |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |